Cite
HARVARD Citation
Liu, C. et al. (2020). The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer letters. pp. 95-105. [Online].